The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' INGREZZA drug to treat movement disorders associated with Huntington's disease, the company ...
WASHINGTON, April 8 (Reuters) - Synchron Inc, a rival to Elon Musk's Neuralink brain implant startup ... No company has received final FDA approval to market a BCI brain implant.
While Neuralink has not provided updates on its clinical trials, Synchron continues to advance in the brain-computer interface market, which has yet to see a company gain final FDA approval for a ...
Pfizer's huge facility in North Carolina produces its first FDA-approved gene therapy, which runs $3.5 million a dose.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The first attempt to win government approval of a psychedelic drug for ... who got dummy MDMA — knew they didn’t get the real drug because they didn’t experience distortions in consciousness ...
The FDA granted accelerated approval to tovorafenib (Ojemda) to treat patients with relapsed or refractory BRAF -altered ...
SILVER SPRING, Md., April 24, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary ...
ImmunityBio finally received FDA approval for its drug ANKTIVA for the treatment of patients with BCG-unresponsive NMIBC with ...
The Swiss pharmaceutical company said Tuesday that the Food and Drug Administration has approved the therapy for the treatment of patients aged 12 and older with somatostatin receptor-positive ...
Roche Holding's Alecensa lung-cancer drug received a new approval from the U.S. Food and Drug Administration as an additional treatment for patients who have undergone surgery to remove their tumor.
Day One Biopharmaceuticals' drug tovorafenib, or Ojemda, received accelerated approval from the U.S. Food and Drug Administration for patients with relapsed or refractory BRAF-altered pediatric ...